Table 1: Comparison of baseline clinical characteristics based on CPR in ESCC.

Cases (n, %)CPRP-value
≤ 0.03 (n, %)> 0.03 (n, %)

Age (years)0.108
 ≤60199 (57.5)120 (54.3)79 (63.2)
 >60147 (42.5)101 (45.7)46 (36.8)
Gender0.077
 Female76 (22.0)42 (19.0)34 (27.2)
 Male270 (78.0)179 (81.0)91 (72.8)
Tumor length (cm)0.242
 ≤ 3.096 (27.7)66 (29.9)30 (24.0)
 > 3.0250 (72.3)155 (70.1)95 (76.0)
Tumor location0.179
 Upper18 (5.2)11 (5.0)7 (5.6)
 Middle164 (47.4)97 (43.9)67 (53.6)
 Lower164 (47.4)113 (51.1)51 (40.8)
Vessel invasion0.025
 Negative289 (83.5)192 (86.9)97 (77.6)
 Positive57 (16.5)29 (13.1)28 (22.4)
Differentiation0.750
 Well47 (13.6)32 (14.5)15 (12.0)
 Moderate230 (66.5)144 (65.2)86 (68.8)
 Poor69 (19.9)45 (20.3)24 (19.2)
TNM stage0.035
 I88 (25.4)65 (29.4)23 (18.4)
 II116 (33.5)75 (33.9)41 (32.8)
 III142 (41.1)81 (36.7)61 (48.8)
CRP (mg/L)<0.001
 ≤ 10.5250 (72.3)219 (99.1)31 (24.8)
 > 10.596 (27.7)2 (0.9)94 (75.2)
ALB (g/L)0.037
 ≤ 40.5179 (51.7)105 (47.5)74 (59.2)
 > 40.5167 (48.3)116 (52.5)51 (40.8)
PALB (mg/L)<0.001
 ≤ 248161 (46.5)81 (36.7)80 (64.0)
 > 248185 (53.5)140 (63.3)45 (36.0)
CAR<0.001
 ≤ 0.3272 (78.6)221 (100)51 (40.8)
 > 0.374 (21.4)0 (0)74 (59.2)

ESCC: esophageal squamous cell carcinoma; CRP: C-reactive protein; PALB: prealbumin; ALB: albumin; CPR: C-reactive protein to prealbumin ratio; CAR: C-reactive protein to albumin ratio; TNM: tumor, node, metastasis.